The role of the scientific advisory board is to assess the suitability of proposals and to provide advice regarding the choice of molecules to be tested in the partnership

It is composed of clinical and pharmacology experts nominated respectively by the Public Partners and the Private Partners by mutual agreement between each group of partners.

Composition

Marc Abramowicz - Génétique médicale, University of Bruxelles (Belgium)
Anne Bousseau - Sanofi-Aventis
Fernando de Andrés Téllez- Spain
Michel Eichelbaum - Institut für Klinische Pharmakologie, Stuttgart (Germany)
Marcel Hibert - Pharmacochemistry of cellular communication laboratory, CNRS, Faculté de Pharmacie de Strasbourg (France)
Bernd Jilma - Department of Clinical Pharmacology, Vienna University Hospital (Austria)
Jorge Kirilovsky - GSK, Les Ulis (France)
Bert Leufkens - Department of pharmacoepidemiology and pharmacotherapy, Faculty of pharmacy, Universiteit Utrecht (Netherlands)
Carole Moquin-Pattey - European Science Foundation (Strasbourg)
Laurent Perret - Servier (Neuilly sur Seine, France)
Agnès Saint-Raymond - Scientific Advice and Orphan Drugs, European medicine Agency (EMEA)
Daniel Scherman - Chemical and Genetic Pharmacology Laboratory, CNRS/Inserm, Faculté de Pharmacie, Paris (France)
Walter Schilling - Roche (Basel, Switzerland)